![](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/ht_210419_rituxan_100_800x450.jpg)
Rituximab Tied to Increased Infection Risk in RRMS
The B-cell–depleting drug rituximab was associated with a twofold increased risk for infection in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment duration or whether patients had received other disease-modifying therapy …